Table 1. Safety Assessment and Virologic Response to 2 Doses of H6N1 Teal HK 97/AA ca Vaccine.

Subjects	No. of Subjects	% infecteda	Virus Detection by Culture in Nasal Wash		Virus Detection by rRT-PCR in Nasal Wash			Symptoms Reported No. with Indicated Illness
			No. Shedding Virusb	Peak Titer mean log10 TCID50/mlc	No. pos. on Day 1	No. pos. after Day 1	Duration of shedding mean daysd	Fever	URI	LRI	Ha	Reactogenicity evente
First Dose	22	32	0	20.6	8	2f	1.3	0	3	0	6	7
Second Dose	18	28	0	20.6	6	2g	1.7	0	5h	1	3	6

Abbreviations used are as follows: No.=Number, pos.=positive, Ha=headache; URI= Upper respiratory illness (includes rhinorrhea, nasal congestion, cough, pharyngitis) LRI= Lower respiratory illness (includes pneumonia, wheezing, rhonchi)

^aInfection is defined as shedding of vaccine virus and/or a four fold or greater rise in serum HI antibody titer, serum neutralizing antibody titer, or in serum H6 HA IgG or IgA titer.

^bNumber shedding virus are those participants who had virus recoverable by culture.

^cViral titers are expressed as log₁₀ TCID₅₀/ml. Peak titers of 0.6 log₁₀ TCID₅₀/ml were assigned to culture-negative samples.

^dMean duration calculated for participants who were rRT-PCR positive.

^eReactogenicity events are defined as fever, nasal congestion, rhinorrhea, pharyngitis, cough, otitis media, pneumonia, headache, myalgia, chills, conjunctivitis, wheezing, rhonchi and epistaxis. Transient abnormalities in blood pressure, pulse and respiratory rate are not included here, nor are adverse events that were thought to be unrelated or not likely to be related.

^f2 participants had virus detected by rRT-PCR days 1 and 2.

^g1 participant had virus detected by rRT-PCR days 1 and 2, the other on days 1 and 4.

^hParainfluenza virus type 3 was detected in nasal washes from 2 participants, and rhinovirus was detected in nasal washes from 1 participant